Abstract
Recent progresses in the molecular and structural understandings in the action of K channel openers for ATP-sensitive K channels and class III anti-arrhythmic agents for HERG K channel are to be reviewed. Based on these progresses, the strategy to identify the useful drugs in these categories will be discussed.